SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC). Escriva, S., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Gradishar, W., Pegram, M. D., Wright, G., Levy, C., De laurentiis, M., Ferrero, J., Bahadur, S., Kim, S., Petrakova, K., Riseberg, D. A., Yardley, D. A., Edlich, S., Hong, S., Rock, E. P., Rugo, H. S. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368300210